These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 27009256)

  • 1. Medicare Part D payments for neurologist-prescribed drugs.
    De Lott LB; Burke JF; Kerber KA; Skolarus LE; Callaghan BC
    Neurology; 2016 Apr; 86(16):1491-8. PubMed ID: 27009256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D.
    de Havenon A; Delic A; Dehoney S; Whetman P; Sheibani N; Callaghan B; Ney J; Esper GJ; Magliocco B; Nair KV
    Neurology; 2021 Apr; 96(16):e2132-e2137. PubMed ID: 33692164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
    Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
    JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
    Sharma M; Vadhariya A; Johnson ML; Marcum ZA; Holmes HM
    BMC Health Serv Res; 2018 Apr; 18(1):236. PubMed ID: 29609611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.
    Fleischman W; Agrawal S; King M; Venkatesh AK; Krumholz HM; McKee D; Brown D; Ross JS
    BMJ; 2016 Aug; 354():i4189. PubMed ID: 27540015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
    DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
    JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare Part D payments for brand and generic drugs prescribed by dermatologists.
    Powell HB; Adamson AS
    J Am Acad Dermatol; 2018 Sep; 79(3):575-577. PubMed ID: 29477736
    [No Abstract]   [Full Text] [Related]  

  • 9. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.
    Duarte-García A; Crowson CS; McCoy RG; Herrin J; Lam V; Putman MS; Ross JS; Matteson EL; Shah ND
    Mayo Clin Proc; 2022 Feb; 97(2):250-260. PubMed ID: 35120693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare payments to the neurology workforce in 2012.
    Skolarus LE; Burke JF; Callaghan BC; Becker A; Kerber KA
    Neurology; 2015 Apr; 84(17):1796-802. PubMed ID: 25832665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
    Morse E; Hanna J; Mehra S
    Otolaryngol Head Neck Surg; 2019 Oct; 161(4):605-612. PubMed ID: 31547772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
    Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
    Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the "rubber effect".
    Ziakas PD; Kourbeti IS; Poulou LS; Vlachogeorgos GS; Mylonakis E
    PLoS One; 2018; 13(6):e0198674. PubMed ID: 29879194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
    Song H; Adamson A; Mostaghimi A
    JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
    Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
    JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
    Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring economic impact of applying daily average consumption limits.
    Flavin BM; Nishida LM; Karbowicz SH; Renner ME; Leonard RJ
    J Manag Care Pharm; 2014 Feb; 20(2):159-64. PubMed ID: 24456317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.